利伐沙班对心房颤动患者安全性的影响

Effect of rivaroxaban on safety of patients with atrial fibrillation

目的 分析利伐沙班对心房颤动患者安全性的影响。方法 采用随机数表法将2021年1月至2022年6月期间山西省运城市中心医院的700例心房颤动患者分为对照组和观察组,每组各350例。对照组患者给予华法林抗凝治疗,观察组患者给予利伐沙班抗凝治疗,两组均治疗6个月后观察疗效。比较两组患者治疗前1 d和治疗6个月后的炎症因子、凝血因子水平,并比较两组的血栓栓塞、出血事件、不良反应情况。结果 治疗前两组患者的超敏C反应蛋白(Hypersensitive C-reactive protein, hs-CRP)、同型半胱氨酸(Homocysteine, Hcy)、纤维蛋白原(Fibrinogen, FIB)、国际标准化比值(International normalized ratio, INR)、活化部分凝血酶时间(Activated partial thromboplastin time, APTT)、凝血酶原时间(Prothrombin time, PT)水平差异无统计学意义(P>0.05),治疗后观察组的hs-CRP、Hcy、FIB水平均低于对照组(P<0.05),INR、APTT、PT水平高于对照组(P<0.05)。观察组的血栓栓塞总发生率(5.14%)、出血事件总发生率(6.29%)均低于对照组(11.71%、22.00%)(P<0.05),观察组的不良反应总发生率(10.00%)与对照组(10.86%)比较差异无统计学意义(P>0.05)。结论 心房颤动患者使用利伐沙班治疗能够较好改善炎症反应和凝血功能,减少血栓栓塞、出血事件发生率,且无明显不良反应,安全性较好。

Objective To analyze the effect of rivaroxaban on safety of patient safety with atrial fibrillation.MethodsA random number table method was used to divide 700 patients with atrial fibrillation at hospital from January 2021 to June 2022 into a control group and an observation group,with 350 patients in each group.The control group patients were treated with warfarin anticoagulant therapy,while the observation group patients were treated with rivaroxaban anticoagulant therapy.The therapeutic effects were observed after 6 months of treatment in both groups.Compare the levels of inflammatory and coagulation factors between two groups of patients 1 day before the treatment and 6 months after the treatment,and compare the thromboembolism,bleeding events and adverse reactions between the two groups.ResultsThere was no significant difference in hypersensitive C-reactive protein(hs-CRP),homocysteine(Hcy),fibrinogen(FIB),international normalized ratio(INR),activated partial thromboplastin time(APTT)and prothrombin time(PT)levels between the two groups before treatment(P>0.05).After treatment,the hs-CRP,Hcy,FIB levels in the observation group were lower than those in the control group(P<0.05),while the levels of INR,APTT and PT were higher than those in the control group(P<0.05).The total incidence of thromboembolism(5.14%)and bleeding events(6.29%)in the observation group were lower than those in the control group(11.71%,22.00%)(P<0.05).The total incidence of adverse reactions in the observation group(10.00%)was not statistically significant compared to the control group(10.86%)(P>0.05).ConclusionRivaroxaban can improve the inflammatory reaction and blood coagulation function,reduce the incidence of thromboembolism and bleeding events in patients with atrial fibrillation,and it has no obvious adverse reactions and good safety.